<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="61325">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02307578</url>
  </required_header>
  <id_info>
    <org_study_id>E2007-G000-409</org_study_id>
    <nct_id>NCT02307578</nct_id>
  </id_info>
  <brief_title>Extended Access Program for Subjects Completing Perampanel StudyE2007-G000-332</brief_title>
  <official_title>An Extended Access Program for Subjects Completing Perampanel Study E2007-G000-332 (Study 332)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      The main objective of the Extended Access Program (EAP) is to ensure that subjects
      participating in Study E2007-G000-332 continue to have access to perampanel until the time
      perampanel becomes commercially available in the country in which they reside.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <phase>N/A</phase>
  <study_type>Expanded Access</study_type>
  <condition>Seizure Disorder Generalized Tonic Clonic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perampanel</intervention_name>
    <description>Perampanel will be available in 2-mg and 4-mg tablets. Subjects will start this EAP with the dose that they were receiving at the end of their participation in Study 332. Doses of perampanel can be adjusted based on clinical judgment.</description>
    <other_name>E2007, Fycompa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        1. Subjects participating in Study E2007-G000-332 (NCT01393743), with at least 52 weeks of
        total exposure to perampanel, and who in the opinion of the treating physician continue to
        benefit from treatment with perampanel.

        Exclusion criteria:

        1. Female subjects who are nursing, pregnant, or planning to become pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Eisai Medical Services</last_name>
    <phone>1-888-422-4743</phone>
  </overall_contact>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 28, 2017</lastchanged_date>
  <firstreceived_date>December 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Perampanel</keyword>
  <keyword>Fycompa</keyword>
  <keyword>Primary Generalized Tonic-Clonic Seizures</keyword>
  <keyword>E2007-G000-332</keyword>
  <keyword>E2007</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
